A
Asceneuron
Develops effective therapeutics for orphan tauopathies
About Asceneuron
Asceneuron is an emerging biotech company focused on discovering and developing groundbreaking therapeutics for neurodegenerative disorders, particularly those with high unmet medical needs such as orphan tauopathies and other related diseases. The company operates in the biotechnology and pharmaceutical market, primarily serving patients suffering from central nervous system (CNS) disorders. Asceneuron's business model revolves around research and development (R&D) of innovative small molecules that have the potential to halt and prevent neurodegeneration. The company generates revenue through partnerships, grants, and potential future sales of its therapeutic products. Asceneuron's R&D pipeline is designed to address significant gaps in current treatment options, aiming to improve patients' lives by providing effective solutions for complex brain diseases. The company actively participates in industry conferences and collaborates with leading experts to stay at the forefront of CNS therapeutic development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Lausanne, Switzerland
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 62.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Genetics and genomics, Spinout, Biotech and Pharma, Longevity, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jul 2024 | $100M | $400M | SR One · Johnson & Johnson Innovation · Sofinnova Partners · EQT Life Sciences | ↗ |
| GRANTOther financing | May 2022 | — | — | Michael J. Fox Foundation for Parkinson's Research | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Asceneuron is 270 monthly website visits, down 79.2% over the last three months. Asceneuron's team declined 10% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Michael J. Fox Foundation for Parkinson's Research
Series A5 investors entered at this stage
Kurma Partners
Sofinnova Partners
SR One
M Ventures
Johnson & Johnson Innovation
Series B and later4 investors entered at this stage
Novo Holdings
EQT Life Sciences
GSK
OrbiMed
Other known investors1 additional known investor
Merck KGaA
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Asceneuron on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Asceneuron’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.